Meiji Seika Pharma and DongA Socio Holdings Initiate Phase I Clinical Trial of DMB3115 a Ustekinumab Biosimilar Candidate

Meiji Seika Pharma Co. Ltd. Headquarters Tokyo Japan President and Representative Director Daikichiro Kobayashi Meiji and DongA Socio Holdings Co. Ltd. Headquarters Seoul Korea CEO Jong Hyun Han DongA today announced the initiation of a Phase I clinical tr...